Search results
Results from the WOW.Com Content Network
The stock of ACADIA Pharmaceuticals (NAS:ACAD, 30-year Financials) appears to be possible value trap, according to GuruFocus Value calculation.
ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid. Stock dips in after-hours trading.
Shares of the California-based company fell 16% in extended trading. The decision comes after two failed attempts to secure regulatory approval for the expanded use of pimavanserin in the ...
The company had a subsequent round of stock offering in May 2007 which raised US$102 million. [23] In September 2020, Acadia Pharmaceuticals acquired clinical-stage biotechnology company CerSci Therapeutics. [24]
Has Wall Street gone a bit overboard punishing ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)? The drug maker’s share price continues to fall Wednesday on the heels of a disappointing 4Q earnings ...
Acadia (ACAD) delivered earnings and revenue surprises of 20.75% and -5.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us